TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$HIMS · Hims Peptide Catalyst: The Valuation Shift Nobody Saw Coming
now playing · $HIMS
$HIMS···bullish· high· postravis holly
FDA peptide panel recommendations create compounding tailwind for Hims & Hers
FDA advisory panel votes to allow compounding of peptides like BPC-157 and KPV will expand Hims & Hers' treatment menu, driving subscriber growth toward 10-20M users and re-accele…
$EUCALYPTUSbullish· mediumtravis holly
Eucalyptus acquisition gives Hims & Hers immediate Australia and Japan footprint
The Eucalyptus acquisition transforms Hims & Hers into a global healthcare platform with instant presence in Australia and Japan, adding international revenue diversification and…